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Abstract: The cell-based approach in gene therapy arises as a promising strategy to provide safe,
targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism,
mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene
therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various
factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this
review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and
cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers
for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of
studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses,
optimization for clinical use is an ongoing challenge. On the way of improvement, genetically
modified MSCs have been combined with various novel techniques and tools (e.g., exosomes,
spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine.
Keywords: non-viral gene delivery; 3D-bioprinting; transfection; mesenchymal stem cell; cell ther-
apy; gene therapy; niosome; COVID-19
1. MSCs
MSCs is a common acronym used to describe a Mesenchymal Stem Cell, Mesenchymal
Stromal Cell, or Medicinal Signaling Cell. However, the debate is still ongoing over which
of these long names best describes MSCs [1]. They are an example of “adult” stem cells
that could be derived from various tissue types.
1.1. MSCs Sources and Features
MSCs have been isolated from almost all tissues [1] and have been reported to play crit-
ical roles in many physiological processes, such as tissue homeostasis, immunomodulation,
and tissue regeneration [2].
Since the famous publications by Alexander Friedenstein et al., on MSCs, half a century
ago, a mounting evidence has been accumulating that bone marrow (BM)-derived MSCs
are capable of differentiating into other cells of mesenchymal lineage (e.g., adipocytes,
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osteoblasts, chondroblasts, myocytes, and tenocytes, etc.,) [3,4]. The authors were able
to isolate the plastic-adherent spindle-shaped cells that were capable of self-renewal and
showed a multi-differentiation potential.
Later on, more reports unveiled a potential pluripotency where these cells can transd-
ifferentiate into cells of other lineages, endodermal (e.g., muscle, lung, and gut cells, etc.),
and ectodermal (e.g., epithelial, and neural cells) [5]. Another interesting feature of MSCs
is their homing ability, meaning that they can migrate into injured tissues where they can
contribute to the physiological processes in ways more than one. (i) They can differentiate
into various local cell types at the injured sites, (ii) they can secrete chemokines, cytokines,
and growth factors that help in tissue regeneration, (iii) they can produce non-classical
secretory vesicles, known as the extracellular vesicles (EVs), (iv) they can effectively com-
municate with stressed/injured somatic cells and transfer their cytoplasmic elements and
organelles (as mitochondria).
In addition to BM, MSCs can be obtained from various sources such as, adipose
connective tissue, synovial fluid, hair follicles, dental pulp, salivary glands, amniotic fluid
and membranes, endometrial lining, peripheral and menstrual blood, placenta and fetal
membranes, umbilical cord blood, and Wharton’s jelly [6].Therefore, due to the above
mentioned appealing features, MSCs have quickly made the transition from benchtop-to-
bedside [7].
1.2. MSCs Identification
To clearly define MSCs, and develop universal criteria for such cell population, the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
Therapy (ISCT) proposed a set of standards for pre-clinical research studies [8].
The minimal criteria of MSCs as determined by the ISCT are the following ones:
The MSCs population must be plastic-adherent when maintained in tissue culture
vessels under standard culture conditions.
1. The vast majority of the MSCs population (≥95%) must express the surface markers
of CD105, CD73, and CD90. At the same time, they must be negative for CD34, CD45,
CD14 or CD11b, CD79a or CD19, and HLA class II.
2. The MSCs population must depict a trilineage differentiation potential to osteoblasts,
adipocytes, and chondrocytes.
3. The MSCs population must exhibit immunomodulatory activity (e.g., T-cell suppres-
sion via induction of indoleamine 2, 3-dioxygenase (IDO) activity by IFN-γ).
Nevertheless, such historical criteria have not been always correlated with the ap-
plicability of these cells in various biomedical purposes. For instance, while CD markers
might stay consistent over successive passages, MSCs tend to lose their differentiation or
immunomodulatory capabilities [9,10].
Despite the aforementioned criteria, ISCT now suggests a considerable flexibility,
particularly when it comes to MSCs the lack of expression of the HLA Class II marker is
conditionally expressed once stimulated by specific cytokines.
Therefore, it is crucial to have the process of MSCs characterization well standardized
to enable accurate comparison of study outcomes, and to guarantee safety and efficacy in
the field. Unfortunately, to date, no single marker has been identified as being exclusively
expressed by MSCs [11]. Yet, the number of MSCs markers (positive and negative) is
expanding over time to help researchers verifying the MSCs features, thus increasing the
confidence in the obtained/transplanted cells.
In addition, various research teams have developed and expanded innovative molecu-
lar markers (e.g., proteomic and epigenetic markers, transcriptome analysis, gene signature,
etc.,). Despite all these trials to address the thorny question about MSCs identity, there is
still little consensus on these characterization methods. Therefore, Arnold I. Caplan [12]
has recently suggested the insignificance of characterizing every cell in every MSCs popu-
lation in vitro. The author believes that most of the propagated MSCs populations have
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become culture-adapted and can no longer display their innate (in vivo) features, nor their
therapeutic behavior, once transplanted.
2. Gene Delivery
The Food and Drug Administration (FDA) has defined gene therapy as “the admin-
istration of genetic material to modify or manipulate the expression of a gene product or
to alter the biological properties of living cells for therapeutic use.” The genetic materials
could be transferred into cells in vitro and in vivo. An essential aspect of gene therapy
depends on designing a suitable gene delivery system to convey the cargo gene into the
target cells. A safe, effective and long-term gene delivery remains an immense challenge
for gene therapy. More than half a century after their introduction as a novel therapeutic
approach, and despite some adverse effects seen in clinical trials, the concept of gene
therapy remains to be acknowledged as a promising therapeutic alternative for various
clinical disorders. However, the obstacles encountered have fueled research efforts that led
to the improvement of gene carriers in terms of their efficacy and safety profiles. Gene ther-
apy, in its various forms, has depicted marked clinical benefits in patients with countless
clinical conditions, such as blindness [13], neuromuscular disease [14], hemophilia [15],
cancer [16], etc.
Over the past decades, genetic engineered stem cells were feasibly used in cell-based
gene delivery, providing long-term therapeutic effects. Furthermore, the continuous re-
search efforts have been directed toward understanding the behavior of individual stem
cells in different tissue microenvironments, in vivo [17]. In parallel, the implementation
of more accurate assays for MSCs and enhancement in gene vehicles have increased the
gene transfer efficiency. MSCs are genetically modified to produce/overexpress a variety
of proteins, in vitro and in vivo, that hold the potential to treat a variety of genetic or ac-
quired diseases, including degenerative disorders [18], or even cancer [19]. The long-term
expression ability of such engineered MSCs provides a lifetime therapeutic approach for
a myriad of clinical disorders. Nevertheless, quality control of the protocols applied in
human gene therapy remains crucial, especially when cells are used as a gene carrier for
treatment of hereditary and acquired diseases.
For successful gene delivery to MSCs, the proper choice of the deliverable nucleic acid
as well as the delivery carrier/method will determine the transfection outcome. Therefore,
in the following section, we will review different types of exogenous nucleic acid cargo
along with various non-viral nanocarriers used with MSCs.
2.1. Nucleic Acid Therapeutics
Nucleic acids act as drugs aim to treat and/or prevent countless intractable diseases,
such as cancer, cardiovascular, neurodegenerative diseases by adding, replacing, editing,
or even inhibiting specific target genes or their products [20]. Such therapeutics are based
upon a multipurpose platform that has almost unlimited capacity to address unmet clinical
needs including vaccination in the current COVID-19 pandemic. Currently, therapeutic
nucleic acids could be roughly classified according to their different structures into DNA
and RNA drugs. Interestingly, the rapid development in the field of RNA therapeutics
has managed to solve the problems of stability, delivery, and immunogenicity. Therefore,
various therapeutics were developed and are now commercially available for various
diseases (summarized in Table 1).
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Table 1. FDA-approved RNA therapeutics for the treatment of human diseases in chronological order, adapted from [21,22].
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Note: Antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs).
Despite such achievements, myriad challenges remain to be overcome before their
impact on patient’s care is fully understood. In this section, we have discussed some of
the most popular nucleic acids used to transfect MSCs, highlighting their advantages and
disadvantages (Summarized in Table 2)
2.1.1. Plasmids
Plasmid-based gene therapy was attempted to correct single gene disorders. The
first federally approved human gene therapy clinical trial for the treatment of adenosine
deaminase deficiency was in 1990. Since then, hundreds of gene therapy protocols have
been approved or deployed. On a molecular level, plasmids are circular, double-stranded
DNA constructs varying in size from <1000 to >200 000 bp containing transgenes. The
main elements in plasmid sequence (e.g., promoters, enhancers, and CpG sites) are known
to govern the rate of transgene expression in a cell-dependent context. Therefore, plasmid
design can dramatically influence transgene expression [23]. Plasmids can encode different
proteins, such as reporter (e.g., Luciferase, EGFP, etc.,) [24,25] or expression (e.g., hBMP,
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RPE65, etc.,) [25,26] genes. Myriad plasmid elements have been studied in the context
of MSCs. For instance, pDNA encoding for EGFP and hBMP7 have been successfully
transfected into MSCs, resulting in fair transgene expression [25]. Their mechanism of
action requires that the plasmid molecules gain access into the nucleus after entering the
cytoplasm. Therefore, nuclear localization is a key limiting step that eventually controls
the efficiency of gene expression.
2.1.2. Minicircle DNAs
Despite their benefit, the translation of pDNA from benchtop-to-bedside remains
highly compromised by their transient expression levels and unwanted backbone elements
(bacterial origins of replication and antibiotic resistance). Therefore, minicircle DNAs
(mcDNAs) were designed with a minimal backbone to meet the clinical requirements for
safe and long-lasting therapeutic transgene expression under the control of mammalian
promoters [27,28]. The decreased backbone size was shown to be directly correlated with
the levels and extent of transgene expression in mammalian cells [29]. Ji-Young Mun and
colleagues had successfully delivered mcDNAs to MSCs by microporation, resulting in an
impressive transfection efficiency, in terms of overexpression of C-X-C chemokine receptor
type 4 (CXCR4) [30]. They reported the ability of transfected MSCs to efficiently migrate to
the injury site in mice. When compared to pDNA, Maria Florian et al., demonstrated that
angiopoietin 1 (ANGPT1) encoded in mcDNAs -transfected MSCs could attain a notably
higher and prolonged secretion levels of ANGPT1 protein, resulting in superior therapeutic
effects animals with acute lung injury [31]. On the other side, Serra J and team reported
insignificant difference in transfection results in BM-MSCs with mcDNAs (MC-VEGF)
compared to pDNA (pVAX-VEGF) [32]. However, they have highlighted the safety aspect
of mcDNAs that come in lower size and have reduced numbers of unmethylated CpG
stretches that have been documented to trigger immune response through TLR9 activation.
Nonetheless, further studies are still warranted to validate whether TLR9 expression is
increased or decreased after transfection when small DNA molecules as mcDNAs are used.
Another major concern is the nuclear transport of mcDNAs. Efficient nuclear transport is
still required to achieve notable transfection efficiency [29]. Moreover, novel methodologies
need to be developed in order to obtain sustainable scale-up production while clinical-grade
quality is maintained.
2.1.3. mRNA
MSCs can be transfected more efficiently with mRNAs than with pDNA and mcDNAs,
most likely due to abolishing the need for nuclear transport and subsequent transcription.
It is noteworthy that mRNA transfection depicts no risk of genome integration. Never-
theless, the protein expression takes place for a shorter duration, which demand repeated
transfection. Such transient transfection could be advantageous in certain applications
in regenerative medicine [33]. To this end, BM-MSCs were transfected with mRNAs en-
coding several reprogramming factors (e.g., Oct4, Klf4, Sox2, cMyc, and Lin28) resulting
in the formation of iPSC colonies [34]. Moreover, mRNA transfection is being used to
simultaneously express multiple proteins such as in the study of Wenbin Liao et al. where
MSCs were transfected with mRNA-mediated delivery of PSGL1/SLeX/IL-10 proteins
to improve the pathogenesis in mice with experimental autoimmune encephalomyelitis
(equivalent to multiple sclerosis in humans) [35]. In general, the simple mRNA delivery
approach may serve as an effective means for monitoring the fate of MSCs in vivo to
effectively treat a wide range of diseases. The mRNAs-encoding antigens could be utilized
as vaccines to provoke the immune system against infectious pathogens, or cancerous cells.
Therefore, it is not surprising to know that the first two COVID-19 vaccines, developed
by Pfizer-BioNTech and Moderna, that received emergency use authorization by the FDA
were mRNA-based. Such breakthrough would not have been possible without critical
recent innovations in production of high-quality mRNA as well as the development of safe
and efficient materials for in vivo delivery.
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2.1.4. Antisense Oligonucleotides and siRNA
In 1978, Zamecnik and colleagues were the first to report the use of synthetic oligonu-
cleotides to silence overexpressed proteins [36]. The antisense oligonucleotides (ASOs) and
small interfering RNAs (siRNAs) are the two most widely used strategies for silencing
gene expression [37]. The concept is basically to choose a target mRNA of physiologi-
cal/pathological importance, to which ASOs or siRNAs are manufactured and used to
block the translation of this particular mRNA [37]. While the ASO functions as a single
strand, siRNA is a double stranded RNA molecule. The passenger strand is lost later,
while the remaining guide strand cooperates with RNA-induced silencing complex (RISC)
to complementarily bind to target mRNA. Such difference between the two approaches
leads to different strengths and weaknesses that affect gene therapy. Based on the oligonu-
cleotides/antisense oligonucleotide technology, Food and Drug Administration (FDA) has
approved several drugs summarized in Table 1 (e.g., Pegaptanib, Nusinersen, Golodirsen,
etc.,) that were marketed over the past decade for treatment of various diseases. On the
other side, only two siRNA drugs, Patisiran and Givosiran were FDA-approved for familial
amyloid neuropathies and acute hepatic porphyria, respectively [38].
Recently, Insúa et al. have recently reported the immunostimulatory effect of the
PyNTTTTGT ONs on the in vitro and in vivo expansion of MSCs [39]. In addition, they
have highlighted the potential clinical application of PyNTTTTGT ONs in tissue repair,
either by augmenting the number of MSCs obtained in vitro, or by increasing the quantity
of MSCs that are made available in vivo for a natural tissue repair process. Intriguingly, the
PyNTTTTGT ONs could be of great benefit if used to complement growth media for MSCs
culture in vitro, thus minimizing the addition of fetal calf serum, an arguable component
of the culture media. Moreover, the ONs can be used in combination with biomimetic
scaffolds to increase the speed of in situ specific tissue development.
Based on their previous findings that knocking down Smurf1 ubiquitin ligase in rat
MSCs would drastically increase bone formation, Patricia García-García and her team have
achieved transient Smurf1 gene silencing in MSCs after single in situ transfection of MSCs
with ASOs, resulting in enhanced osteogenesis and mature bone formation in vivo [40].
In terms of cytotoxicity, the ASOs are considered cytotoxic due to their exaggerated
pharmacology, resulting from their binding to off-target RNAs, producing undesirable
effects. In addition, high doses of ASOs may depict non-antisense effects [41]. In vivo, ASOs
administration can induce acute toxicity through activation of the transient complement
cascade and the inhibition of the clotting cascade. Another sub chronic toxicity is due to
the immunogenicity of ASO, manifested by splenomegaly and lymphoid hyperplasia [42].
Sophie Raisin and her co-workers have efficiently transfected murine BM-MSCs with
siRNAs targeting the runt-related transcription factor (Runx2) which is known to be ex-
pressed in MSCs and associated with bone differentiation [43]. They provided evidence that
the Runx2 gene was successfully silenced. In another study, E.M. André et al. transfected
MSCs using siRNA technology to silence the repressor Element-1 silencing transcription
(REST) factor, therefore enhancing the neuronal differentiation. The induced inhibition of
REST over time have induced significant neuronal commitment associated with a higher
expression of neuronal markers [44].
2.1.5. Aptamers
Aptamers, also known as “synthesized antibody,” are a special group of short single-
stranded DNA or RNA oligonucleotides that bind strongly to their target proteins, ex-
tracellularly or intracellularly, affecting their functionality. Therefore, they are currently
used in several clinical trials [45]. Meng Wang and coworkers developed a novel MSCs
aptamer “HM69” based on which, they generated HM69-functionalized nanoparticles
(NAB) [46]. Their results demonstrated that aptamer HM69 could recognize and bind
to MSCs with high affinity, resulting in the recruitment of endogenous MSCs. Further,
the NAB nanoparticles enhanced endogenous stem cell homing and promoted bone de-
fect repair. They concluded that MSCs aptamer HM69 is uniquely attractive for targeted
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MSCs enrichment. Moreover, the NAB nanoparticles have great potential application as a
non-invasive tissue-engineering approach for the treatment of osteochondral lesions.
Recently, Yujian Zou and team selected an aptamer, termed seq3, with high specificity
and affinity for mouse BM-MSCs [47]. They developed Seq3-based activatable aptamer
probes (AAP) to monitor transplanted BM-MSCs in a mouse model of chronic kidney
disease. The AAP have substantially minimized the background signals, thus considered a
promising tool for determining the survival status of transplanted BM-MSCs. Nevertheless,
aptamers are prone to quick degradation in biological media due to interactions with
biomolecules. Many aptamers have been shown to degrade in blood as quickly as a
few minutes, which is far too short for most medical applications. Moreover, since most
aptamers are relatively small molecules (5 to 15 kDa), they are easily excreted from the
body through the kidneys. Interestingly, conjugation of aptamers with large PEG ligands
to increase their molecular weight above around 40 kDa could reduce their excretion via
the kidneys.
2.1.6. Nucleic Acid Enzymes (Ribozymes and Deoxy Ribozymes)
Ribozymes are another type of NA therapeutic that hold the ability to catalyze the
cleavage of phosphodiester bond of specific target RNA transcripts, guided by antisense
arms. They eventually regulate gene expression using a catalytic core [48]. In addition to
the natural RNA ribozymes, DNAzymes could be obtained through screening technologies,
in vitro. The DNAzymes are single-stranded DNA molecules that depict natural catalytic
activity. Moreover, they are capable of recruiting small molecules, metal ions, and bacterial
pathogens for catalysis. Thereafter, they are used as indicators for these molecules in
the diagnosis of certain diseases. Moreover, once coupled with aptamers, they make
aptazymes that enable specific detection of a wide variety of signals [49]. Nevertheless,
the stability of DNAzymes and ribozymes remains one of the main obstacles that needs
to be circumvented before their applications are widely used in treating human diseases.
Moreover, other issues as the structure design, delivery, and expression need to be further
explored and solved.
In their study, Sophia Millington-Ward and her team investigated a gene therapy for
COL1A1-associated dominant-negative forms of OI in BM derived human mesenchymal
progenitor cells (MPCs) using a hammerhead ribozyme (Rzpol1a1) [50]. The hammer-
head ribozyme has two arms that bind to and cleave the phosphodiester backbone of the
mRNA by hydrolysis, thus promoting mRNA degradation and hampering its translation.
Therefore, ribozymes have been shown to downregulate COL1A1 transcripts specifically at
mutation sites.
Interestingly, DNA enzymes are easier to manufacture compared to their ribozymes
counterparts. Moreover, they have less restrictions regarding the cleavage sites, thus
supports the choice of targeted cleavers for systematic screening [51]. These advantages,
together with their potential in various animal models make DNA enzymes a promising
therapeutic agent. However, to the best of our knowledge, they have not been used to
modify gene expression in MSCs yet.
2.1.7. MicroRNAs
MicroRNAs (miRNAs) are endogenous non-coding short (20–25 nucleotide) RNA
molecules that regulate post-transcriptional gene expression by targeting mRNA for cleav-
age or translational repression. Overall, miRNAs are tremendously important in controlling
cell differentiation and developmental patterning in animals and plants and were found
to be implicated in the pathogenesis of many diseases, such as cancers, viral infections,
immune diseases, cardiovascular diseases, wound healing, to mention a few. Therefore,
miRNA mimics/inhibitors currently in preclinical development have shown potential as
novel therapeutic agents. miRNAs are considered critical regulators of the differentiation
of BM-MSCs. The two key components in the biogenesis of canonical miRNAs, silencing
Dicer or Drosha, block both adipogenic and osteogenic differentiation of BM-MSCs [9]. In
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their study, Yueqiu Chen and team have achieved transfection of rat BM-MSCs with the
agomir or antagomir of miR-133 [52]. Subsequently, they documented significant decrease
in hypoxia-induced apoptosis of cells transfected with miR-133 agomir, while the apopto-
sis rate increased in MSCs transfected with miR-133 antagomir. More importantly, once
those miR-133 overexpressing MSCs were transplanted into rats with acute myocardial
infarction, a significant improvement in cardiac function was reported compared to their
control animals. Further studies indicated that both the inflammation level and the infarct
size decreased in miR-133-MSC-injected rat hearts.
In a thought-provoking approach, J. Carthew et al. have developed a simple system
for in situ transfection of miRNA and demonstrated its convenience to boost osteogenic
differentiation of MSCs within a soft hydrogel scaffold [53]. The addition of PEI-complexed
miR-100–5p and miR-143–3p maintained a steady and gradual availability of target miR-
NAs to the encapsulated cells, more effectively than encapsulating pre-transfected MSCs.
This study opens the door for further tailoring the diffusion rate/timing for or miRNAs
diffusion.
2.1.8. Short Hairpin RNA (shRNA)
Shortly after the cellular mechanism of RNAi was first described, research on such
powerful technique has popped up. This included designing better methods for the
successful delivery of shRNAs into mammalian cells. Once inside the cells, Dicer converts
the hairpin structure of shRNA into siRNA that ultimately utilizes the RISC mechanism
to induce gene suppression. In addition to their fewer off-target effects, shRNAs are
advantageous over siRNAs due to the following: (a) Their ability to use viral vectors for
delivery to overcome the difficulty of transfecting certain cell types; (b) the possibility to
control shRNA expression through inducible or tissue specific promoters; (c) the ability to
co-express them with a reporter gene.
In their study, Yingwei Zhu and colleagues have transduced MSCs with shRNA
inhibiting the expression of metalloproteinase 1 (TIMP-1) [54]. They investigated the
therapeutic effect of TIMP-1-silencing MSCs in a rat model of CCl4-induced liver fibrosis
when transplanted intravenously. They indicated that transplantation of MSCs expressing
TIMP-1-shRNA could inhibit the progression of liver fibrosis and possibly restore the
liver function. In another work, Natasha Baker and her coworkers have reported that
shRNA-mediated knockdown of caveolin-1 expression enhances MSCs proliferation and
osteogenic differentiation [55]. To establish a stable knockdown, they infected human
BM-MSCs with a lentiviral construct harboring shRNA targeted against caveolin-1.
In a different approach, Yoon and team achieved a knockdown for nuclear factor
erythroid-derived 2-like 2 (NRF2) in early passage MSCs using two different shRNAs
(shRNA-1 or shRNA2) [56]. Such regulation of gene expression helped them studying
the role of NRF2 in protecting MSCs against cell death and apoptosis caused by oxidative
stress and retaining their multi-differentiation potential.
However, nucleic acids are believed to hold the ability to manipulate cellular functions,
leading to the development of specific and safe novel medicines, it is noteworthy to
highlight that nucleic acids still have several drawbacks for their development as drugs.
Their chemical modifications have significantly boosted their specificity and stability
properties against nucleases, without losing their biological properties. Nevertheless, the
delivery of most of nucleic acids remains as a major hurdle toward the development of
nucleic acids as therapeutic agents. Therefore, in the next section we discuss the nucleic
acid delivery carriers to MSCs with much emphasis on the lipid-based carriers.
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Table 2. A summary of nucleic acids used to transfect MSCs: The advantages and disadvantages.
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2.2. Nucleic Acid Delivery Carriers
Different from traditional therapeutics, the cellular internalization “endocytosis” mech-
anism is a major limiting step for nucleic acids. Therefore, the need for delivery vectors to
transport them to the cell nucleus/cytosol is crucial [61,62]. Traditionally, there are two
main categories for gene delivery carries, namely the viral and non-viral ones (illustrated
in Figure 1). The viral gene carrier, such as adenovirus, retrovirus, and lentivirus, are
used to deliver genes into cells via the process of transduction. Despite the high trans-
duction efficiency and stable gene expression that viral vectors tend to provide, myriad
challenges remain to be circumvented (e.g., immunogenicity, mutagenesis, limited DNA
loading capacity, taxing large-scale production, etc.). Interestingly, non-viral gene carriers,
including lipid-based DNA therapeutics, are considered promising alternatives to their
viral counterparts as they hold the potential to address most of such limitations [63,64].
Moreover, the transient gene expression provided by most of these systems is compatible
with normal tissue repair. Currently, several non-viral tools are commonly used for gene
delivery, such as lipids nanoparticles NPs (e.g., solid lipid NPs, liposomes, niosomes, etc.,),
polymers (e.g., poly (β-amino ester)s [60], heparin and chitosan-based NPs, etc.,) [65],
and inorganic NPs (e.g., superparamagnetic iron oxide, silica NPs, quantum dots, gold
NPs, carbon nanotubes, calcium phosphate NPs, etc.,). While such systems can be used to
transfect MSCs with various nucleic acid, DNA and RNA, cargo, the development of an
optimal non-viral vector to transfect such valuable cells remain a challenging goal.
Figure 1. Viral and non-viral carriers of nucleic acids. NLC: nanostructured lipid carrier, SLN: solid lipid nanoparticles,
CP: cell penetrating, NPs: nanoparticles.
Lipid-based gene delivery systems became one of the first non-viral gene delivery
systems to be approved by the FDA and other regulatory agencies [66]. Lipid nanoparticles
(LNP) are interesting drug/gene delivery systems for many reasons. For instance, they can
carry both lipophilic and hydrophilic categories of drugs to specific cells/tissues without
being toxic, they are also famous for their good biocompatibility and biodegradability.
Therefore, in this section, we will emphasis some of their merits and applications.
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2.2.1. Lipid-Based Genetic Carrier
Solid Lipid Nanoparticles (SLNs)
Solid lipid nanoparticles (SLNs), formerly known as lipospheres, are one of the
pharmaceutical nanocarriers that hold great promise for controlled drug delivery. SLNs
are typically composed of biodegradable and safe lipidic components [67]. They can
carry a variety of therapeutics, such as small drug molecules, large biomacromolecules
(polysaccharides, etc.,), genetic material, in addition to the vaccine antigens due to their
cationic lipid content that provides a positive surface potential favoring the binding to
nucleic acids such as like pDNA, siRNA, miRNA [68].
Chongrui Jin et al. have recently constructed nanosphere-small MyoD activating RNA-
bladder acellular matrix graft scaffold loaded with adipose-derived stem cells (ADSC) to
explore its effect on smooth muscle regeneration and bladder repair function in rats [69].
They have found that saRNA-MyoD lipid NPs promote a sustained release of MyoD and
smooth muscle regeneration with scaffold degradation in rats. The bonding of saMyoD to
the lipid NPs have provided a targeted sustained release system, evading undesired off
target effects. Therefore, this method could reduce the potential risk of free diffusion of
cytokines in vivo, thus promoting their efficient utilization.
Liposomes
Liposomes are spherical vesicles having an aqueous core enclosed by one or more
phospholipid bilayers or lamellae. They are mainly composed of several structural compo-
nents such as, phospholipids and cholesterol. Liposomes are assembled as one or more
simple or functional concentric lipid bilayer membranes that enclose hydrophilic spaces
(Figure 2).
Figure 2. Schematic structure of liposomes showing different compositions. [70]. CC BY 4.0 license.
Over the years, different methodologies for large scale liposome preparation have
been developed and optimized recently by including various synthetic modifications to
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the phospholipid component to enhance tissue-specific targeting and evading detection
and clearance by the immune system. Therefore, several commercially available liposomes
(e.g., Lipofectamine® 2000, TransFast®, ScreenFect®, Lipofectin 2100®, etc.,) are widely
used for gene delivery purposes in vitro, in vivo. Moreover, liposome-based products
are used in patients enrolled to clinical trials, up to phase IV [71]. Recently, Qiao et al.
have used one of the commercially available liposomes (Lipofectamine 2000) to transfect
BM-MSCs with miR-203 mimics and miR203 inhibitor [72]. They found that overexpression
of miR-203 increased the level of osteogenic related genes but decreased that of adipogenic
related genes, while knockdown of miR-203 led to the opposite results. Similarly, the same
liposome transfection reagent has been used as a positive control in several transfection
experiments on MSCs as well as other cell lines [25,61,62,64,73]. Nonetheless, the success
of lipofection is controlled mainly by their mechanical properties, route of administration
and delivery barriers (e.g., in vivo stability, permeation of particles through tissues, low
target cell specificity, reticuloendothelial system (RES), subcellular localization, etc.) that
they must overcome to ultimately preform their function.
Niosomes
Niosomes are membranous vesicles composed mainly of non-ionic surfactants, am-
phipathic compounds with a net neutral charge. The non-ionic surfactant component of
niosomes tend to be oriented in a way that hydrophilic ends face the aqueous phase (out-
ward), whereas the hydrophobic ends face inward to form a closed bilayer structure that
could enclose solutes in the aqueous solution. Consequently, the closed bilayer structure of
niosomes has hydrophilic inner and outer surfaces, with a sandwiched lipophilic area in
between. The non-ionic surfactants are safe and affordable for the use in biomedicine as car-
riers for genes or hydrophilic/hydrophobic drugs [74]. Niosomes are prepared by various
methods, such as ether injection, sonication, and microfluidics, to mention a few [75].
Owing to their structural similarities with liposomes, niosomes were proposed for
targeted drug delivery by promoting sustained drug release into specific cells and tissues.
Moreover, their efficacy and safety have been proven in numerous pre-clinical and clinical
studies that emphasized the biocompatibility, biodegradability, and low immunogenicity of
niosome components (i.e., non-ionic surfactants, cholesterol, fatty acids, charged molecules,
etc.,) [76]. Cytotoxicity is a major factor that should not be overlooked when niosomes are
used as a therapeutic tool. Niosomes are way more tolerated by transfected cells compared
to their anionic or cationic counterparts [77]. Therefore, the combination of relatively
cytotoxic cationic lipids with non-ionic molecules to formulate niosomes could reduce
such undesirable toxicity [78]. In addition to the aforementioned properties, the low cost
and easy preparation of niosomes have paved their way to stand out versus liposomes (as
summarized in Table 3) and other conventional systems for drug/gene delivery.
Table 3. Niosomes versus liposomes as gene/drug carriers. [79].
Niosomes Liposomes
Components Surfactant Phospholipids
Component availability High Low
Component purity Good Variable
Preparation and storage No special conditionsrequired
Inert atmosphere and low
temperature
Stability Very good Low
Cost Low High
In a recent study, MSCs line has been engineered to overexpress hBMP7 by transfect-
ing the hBMP7 gene using the pUNO1-hBMP-7 plasmids and novel cationic niosomes.
Two days following transfection, cells secreted up to 1460 pg of hBMP7 protein per ml [25].
Such amount of overexpressed hBMP7 protein was sufficient to induce spontaneous osteo-
genesis in vitro. Therefore, we suggested that BM-MSCs overexpressing hBMP-7 could be
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considered as a reliable delivery tool of hBMP-7 to target tissues. In addition, they are still
considered as proliferating and bone-forming cells to target sites where bone regeneration
is needed.
3. Applications of Engineered MSCs
As mentioned above, there are various approaches through which genetically modified
MSCs can be applied to achieve therapeutic impact in different clinical conditions. MSCs
were used to deliver a myriad of growth factors [80,81], cytokines [82], transcription
factors [43], or even suicide gene [83,84] with various potential clinical purposes. Some of
these applications are reviewed next and summarized in Table 4.
3.1. Bone and Cartilage
MSCs are well-known of their natural ability to differentiate into cells with bone and
cartilage phenotypes. Moreover, they are reported to induce a paracrine effect that boosts
the natural repair process in case of injury. This latter mechanism was the basis for most
of the studies using MSCs to deliver/overexpress various types of factors known to be
key in repair mechanisms, thus being therapeutically useful. Among those factors were
the BMPs, BMP2 [85–87], and BMP7 [25]. BMPs are known for their ability to enhance
bone regeneration through various mechanisms, such as signaling the chemotaxis, in
addition to proliferation, and differentiation of osteoprogenitor cells. As a pro-angiogenic
growth factor, MSCs overexpressing VEGF was also used to improve the vascularity of
microenvironment [88]. Other mechanisms by which engineered MSCs boosted bone
regeneration was to transduce transcription factors as Trb3 [89] or miRNAs (as miR-
5106) [90] to manipulate cell differentiation, or to transiently silence the Smurf1 gene [40].
3.2. Central Nervous System
Many neurological disorders are difficult to treat due to the high sensitivity of neurons
to the hostile environment following the injury/pathology. In addition, to the doubtful
regenerative capacity in the first place. Moreover, the blood-brain barrier (BBB), as a
tough gatekeeper, makes it difficult to treat the diseases of the CNS, including cancer.
However, owing to their ability to cross the BBB [91], MSCs are proposed as a useful carrier
of genes/drugs to the CNS. For instance, they can be used to deliver growth factors as
hepatocyte growth factor (HGF) or fibroblast growth factor (FGF) 21, to improve repair
after a spinal cord [80] or brain injury [92], respectively. Although cerebral ischemia is
considered a major clinical problem worldwide, the treatment available is quite limited. In
that regard, MSCs used to deliver genes as HGF [81], IL-10 [82], VEGF [93],or CXCR4 [94]
were found to boost neovascularization and enhance nerve tissue regeneration in animal
models of cerebral ischemia.
3.3. Myocardial Ischemia
Ischemic heart disease is a leading cause of death worldwide. Improvement of blood
flow to the heart muscle is considered a crucial treatment option. As mentioned above with
CNS, MSCs could be quite helpful to improve the microvasculature of the heart muscle
through delivering key growth factors, such as VEGF [95,96] and HGF [97]. The activated
serine/threonine kinase AKT, as the major substrate to phosphoinositide 3-kinase (PI3K),
is reported to control various cellular functions (e.g., cell proliferation, metabolism, and
survival, etc.,), in addition to being able to boost angiogenesis. The AKT, successfully
delivered to the myocardium via the AKT-overexpressing MSCs, was reported to induce
a dramatic early reduction in the infarct size and improve the cardiac function [98]. In
another approach to activate the AKT/ERK-related pathway, MSCs overexpressing miR-
126 were able to boosted angiogenesis and improved cardiac function in the infarcted area
of the myocardium of mice [99].
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3.4. Cancer
Following cardiovascular disorders, cancer ranks the second most common cause of
death in many countries. Each year, half of the tens of millions of patients diagnosed with
cancer eventually die from it. Over the past two decades, there have been various trials
to use genetically modified MSCs a possible therapeutic approach. One of such attempts
was to overexpress the suicide gene thymidine kinase (TK) either alone [83,84], combined
with valproic acid (VPA) [100], or with tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) [101] to promote cancer cell death, thus regressing tumor growth. Other
studies used a different strategy depending on the overexpression of antitumor cytokines,
as IL7 [102] and IFN-β [103]. Moreover, various approaches were reported to combat tumor
vascularity using genetically modified cells that overexpress anti-angiogenesis molecules,
such as Endostatin [104] and kringle1-5 protein [105]. Another recent study used MSCs as
vehicles to deliver immuno-modulatory proteins, IL7 and IL12, to improve the anti-tumor
impact of CAR T cells in a transplant tumor model [102].
3.5. COVID-19
In quick response to the COVID-19 pandemic, MSCs are being utilized in several
clinical trials studying SARS-COV2-induced pneumonia [106]. For instance, Zikuan Leng
et al. have recently reported that the transplantation of MSCs, that do not express ACE2
and TMPRSS2, had improved pulmonary function among other parameters in COVID-19
patients [107]. Owing to the unique immunomodulatory capacity of MSCs, the serum levels
of pro-inflammatory cytokines and chemokines were dramatically lowered in patients
after intravenous transplantation of MSCs. Moreover, the increased IL-10 and VEGF were
behind the improved repair of lung tissue. In general, acute respiratory distress syndrome
(ARDS) results in increased pulmonary inflammation and vascular permeability causing
high mortality in critically ill patients. MSCs were found to reduce such abnormalities
through the secretion of paracrine/endocrine factors and/or direct interaction with host
immune cells. Moreover, when MSCs were transfected to overexpress the angiopoietin-1
protein, a vascular protective factor, pulmonary endothelial permeability was notably
reduced in mice with ARDS.
The alpha-1 antitrypsin (AAT) protein is acknowledged for being one of the key
players in the acute phase anti-inflammatory response [108]. Therefore, MSCs engineering
appears to be a promising strategy to overexpress the AAT protein, not only to treat AAT
deficiency, but also to augment AAT in patients with normal plasma levels of AAT [109].
This approach is quite flexible as patients would benefit from the versatile secretome of
MSCs in addition to the expression of AAT protein [110]. If fact, several gene delivery
trials were conducted using various virus carriers. Nevertheless, results obtained, to date,
did not achieve protective levels of AAT protein in the target lung tissue [111]. Therefore,
MSC-based gene therapy could be a promising therapeutic tactic to circumvent the problem
of targeted delivery and satisfactory level of gene expression [1], especially when we know
that most of the intravenously administered MSCs seem to be trapped in the lungs during
the first pass [112].
3.6. Other Applications
Various other clinical conditions could benefit from MSCs as a gene delivery carrier.
For instance, human telomerase reverse transcriptase enzyme (hTERT)-transfected MSCs
could differentiate into islet-like cells that were found to reverse hyperglycemia in diabetic
mouse model [113]. Moreover, in complicated skin wounds [114], the gene delivery system
could be used as a multifaceted approach to enhance the healing process via VEGF-induced
angiogenesis, hand in hand with combating bacterial infection.
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Note: 4HP4: tetrameric form of cell-permeable peptide; CPP: cell-permeable peptide; HSV: herpes simplex virus; tTATop-BMP-2: tetracycline
transactivator and BMP-2 cDNAs; BA-PEI: bile acid-modified polyethyleneimine; PMAA: polymethacrylate acid; CMV: cytomegalovirus;
AT-MSCs: adipose tissue-derived MSCs; HIF-1 α: hypoxia-inducible factor-1α; CDY::UPRT: cytosine deaminase and uracil phosphoribosyl
transferase; GAM: gene-activated matrix; GDEPT: gene-directed enzyme prodrug therapy; MVs: microvesicles; DBM: demineralized bone
matrix; PLL-PEI: polylysine-modified polyethylenimine; hPMSCs: human placenta-derived MSCs; HSV: herpes simplex virus; MCAO
I/R: middle cerebral artery occlusion ischemia/reperfusion; SD: Sprague-Dawley; MI: myocardial infarction; hEndo: human endostatin;
UCB-MSCs: umbilical cord blood-derived MSCs.
4. Future Perspectives
In addition to all of the abovementioned considerations about the MSCs population,
the other stakeholders of gene delivery (e.g., nucleic acids, carriers, and transfection
technique) should be optimized in a holistic approach for better transfection of MSCs.
However, the transfection efficiency remains a fundamental limitation for applications that
make use of non-viral gene transfer to MSCs, therefore innovative approaches (summarized
in Figure 3) for improving non-viral gene delivery are being investigated, as described next.
4.1. Exosomes
As mentioned before, the pleiotropic effects of MSCs are now believed to be medi-
ated mainly by the paracrine secretion of various molecules [6]. Exosomes are nanoscale
extracellular vesicles that are considered an important class of such paracrine mediators.
Myriad studies have reported that exosomes were behind the therapeutic impact of MSCs
in various experimental models. Therefore, exosomes were among the main pillars of the
novel cell-free therapeutic approach for treatment of a variety of disorders [122]. Moreover,
exosomes hold a great potential as drug delivery vehicles due to their natural properties
(e.g., cargo molecules, intrinsic long-term circulatory capability, excellent biocompatibility,
etc.,) [123] rendering them ideal carrier for a variety of proteins and nucleic acids. Nev-
ertheless, there is still an unmet need to develop an effective method for loading specific
proteins/nucleic acids into exosomes [124].
In their recent work, Ran Kim et al. have injected U87 glioma cells into mice exposed
to exosomes derived from miRNA-584-5p-transfected MSCs, to confirm the influence of
exosome miRNA on the progression of glioma [125]. Their results were encouraging
enough to recommend exosomes derived from miRNA-transfected MSCs as a new targeted
cancer therapy. In another study, silencing of IL 10 (IL10 knock-down) was done by Alfonso
Eirin et al. to adipose tissue MSCs (via siRNA) from which EVs were obtained to investigate
the particular renoprotective role of the IL10 content of EVs [126]. Similar to the effect of
AT-MSCs, their EVs were found to attenuate renal fibrosis, ultimately improving stenotic
kidney function. Notably, the beneficial effects of EVs were blunted in pigs that received
IL-10-silenced EVs, supporting an important contribution of this cytokine to several aspects
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of renal function. In this way, engineered EVs could be obtained and used in cell-free
therapy.
Another interesting approach is the exogenous loading of EVs, after their isolation,
through various methods, such as electroporation, simple incubation, chemical transfection,
or others. For instance, chemical transfection methods have been utilized to load siRNA
into EVs by simply incubating exosomes with siRNA-lipofectamine 2000 complexes (siRNA
embedded in lipid micelles). However, further studies are still needed to enhance the
transfection efficiency and to discard the excess transfection reagent.
Figure 3. Some innovative approaches for improving gene delivery by MSCs.
4.2. Spheroids
MSCs can be used to treat osteoarthritis, yet the therapy is hindered by massive
MSCs death after intra-articular implantation. Furthermore, MSCs barely secrete IL-4,
a potent anti-inflammatory cytokine. Seuk Young Song et al. suggested a combination
of both Il-4 gene transfection (using GFP-expressing plasmids and a cationic liposome-
based reagent) and spheroid formation to potentiate the therapeutic efficacy of MSCs
for osteoarthritis [127]. MSCs in spheroids depicted better survival compared to naïve
MSCs in vitro and in vivo. Despite the low secretion of IL-4 protein (7 ng mL−1/12 h),
transfected MSCs spheroids induced significantly more cartilage protection and pain relief
than conventional naïve MSCs.
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4.3. Scaffolds
In general, 3D-scaffolds represent a promising modality in promoting tissue regen-
eration and treating diseases. In general, the 3D environments influence integrin-based
interaction between MSCs and the surrounding extracellular matrix, resulting in modu-
lation of cell signaling, that would eventually regulate gene expression [128]. Therefore,
significant attention was directed toward exploring the potential of combining non-viral
vectors, as liposomes, to design vector-scaffold composite systems for various biomedical
applications. Liposome-loaded scaffolds are designed mainly to combine the advantages
of both liposomes’ biocompatibility and scaffolds’ strength, enhancing their applications in
in-tissue regeneration for bone, teeth, spinal cord, and skin disorders.
In a recent study, Li-Ming Li and colleagues applied a three-dimensional gene trans-
fection technology by transfecting MSCs with brain derived neurotrophic factor (BDNF)
gene using the liposomal gene carrier, ScreenFect® A [129]. To improve gene expres-
sion as well as cellular survival after in vivo implantation of MSCs, an adhesive peptide
(PPFLMLLKGSTR)-modified hydrogel scaffold was constructed using hyaluronic acid.
Compared to untransfected MSCs, the transfected cells exhibited sustained gene expression
and prolonged survival in the 3D-scaffold in vitro, and improved spinal tissue integrity,
inhibited glial scar formation, and alleviated inflammatory response in vivo.
In another study, Jiabing Fan et al. reported that Tribbles homolog 3, an intracellular
kinase-like molecule that modifies cellular survival and metabolism, does serve as a key
molecular switch controlling adipocyte-osteoblast differentiation of MSCs, in addition to
regulating MSCs lineage fate through the BMP and Wnt signaling [89]. They employed
scaffold-mediated local Trb3 transfer (plasmid-expressed Trb3 using Lipofectamine® 2000
transfection of MSCs) to improve bone healing in a clinically related mandibular bone
defect model.
In a similar context, our group has evaluated a new combination of niosomes, non-
viral pDNA carrier, and hyaluronic acid HA hydrogel scaffolds [130]. Both components
are widely studied owing to their safe and biocompatible profile. We evaluated different
types of niosomes varying in their cationic lipid, helper lipid, and non-ionic surfactant
composition. The ability of pDNA-niosome complex-loaded HA hydrogels was found to
hold little or no particle aggregation, allow for extensive cell spreading, and to efficiently
transfect encapsulated mMSCs with minimal cytotoxicity. Such in vitro model could be
utilized to design novel and effective platforms for in vivo local non-viral gene delivery
applications (Figure 4).
Figure 4. Nioplexes-loaded HA hydrogels for transfection of MSCs [130]. CC BY 4.0 license.
4.4. D-Bioprinting
Tissue engineering of complex solid organs has been such a challenging approach
which led to the development of bioprinting as a game changer technology holding great
promise for versatile biomedical applications. In general, bioprinting involves the spatial
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assembly of different cells, bioinks, and supporting biomaterials, to obtain constructs that
mimic the biological and/or mechanical functions of natural tissues (Figure 5).
Figure 5. Multi-material bioinks used to bioprint 3D constructs for various biological applications [131].CC BY-NC-ND 4.0.
However, it has been limited by the availability of functional primary human cells
and the associated complexity with their use in a clinical setting. In addition, the reten-
tion/control of functional cell population within the implanted construct in vivo requires
an accurate delivery of regulatory cues (e.g., growth factors) within the printed construct to
eventually harness those cells. Engineering cells, through gene delivery, to locally produce
those regulatory molecules represents an alternative approach to precisely control cells’
longevity, proliferation, and function within the engineered tissues. The ex vivo cell trans-
fection and their subsequent transplantation in vivo within bioprinted constructs have
offered high levels of protein expression over prolonged periods of time. As an alterna-
tive, the incorporation of the gene of interest and its delivery carrier into a biodegradable
construct, to form a gene activated matrix/bioink, offers a localized and sustained gene
delivery to transplanted and host cells, in situ.
In their recent study, Gonzalez-Fernandez T et al. aimed to engineer mechanically
functional composites for a range of applications in orthopedic medicine [132]. They
have explored the two abovementioned approaches (ex vivo and in situ) to transfect
BM-MSCs with genes for osteogenic (BMP2) or chondrogenic (combination of TGF-β3,
BMP2, and SOX9) differentiation within networks of 3D-printed thermoplastic fibers. They
succeeded to use nanohydroxyapatite particles, and the arginine-alanine-leucine-arginine
amphipathic (RALA) peptide as delivery carriers for pDNA to transfect BM-MSCs prior to
3D-Bioprinting and to prepare gene-activated alginate-methylcellulose bioinks.
As mentioned earlier, the delivery of naked pDNA into stem cells without a vector
remains a big challenge. Therefore, Nien-Chi Huang et al. have recently developed a
rapid and easy method to transfect naked pDNA for GATA-binding protein 4 (GATA4)
into human umbilical cord-derived MSCs (hUC-MSCs) by co-extruding naked pDNA
and hUC-MSCs with a biodegradable thermo-responsive polyurethane (PU) hydrogel
through a micro extrusion-based transient-transfection system [133]. The optimized PU
hydrogels induced GATA4-transfected hUC-MSCs to differentiate into cardiomyocyte-like
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cells within 2 weeks in vitro. Furthermore, they were able to restore the cardiac function
in vivo in zebrafish.
5. Challenges
Despite the versatile applications of MSCs in biomedicine, many concerns still war-
rant attention for process optimization such as, timing, dosage, and administration route
of transplanted MSCs. For hMSCs to be used in therapy, a large population of hMSCs
is needed, thus cells propagated by in vitro expansion. However, the phenotypic and
functionality changes following the in vitro expansion of hMSCs are considered a ma-
jor concern thus far. The effects of replicative/ late-passage senescence on the various
functional aspects of MSCs merit further research. In addition, long-term in vitro ma-
nipulation or culture of MSCs may lead to genetic instability and various chromosomal
abnormalities [134]. This might be due to the diminished efficiency of DNA repair systems,
leading to building up of DNA mutations of various types (e.g., deletions, duplications,
rearrangements). The in vitro expansion of MSCs is also known to reduce their prolifera-
tion and differentiation capacity, bring about cell senescence, and cause various epigenetic
changes [135]. Thereafter, younger passages of MSCs are way desirable for transplantation
in vivo.
Another factor that impacts MSCs efficacy and/or number is the proper choice of
cell source. It is difficult to obtain enough quantities of healthy autologous MSCs with
high activity from patients suffering from chronic diseases as diabetes, or rheumatoid
arthritis [136]. Moreover, MSCs obtained from subjects with old age or from those with
medical conditions are known to hold less therapeutic effects than those obtained from
healthy individuals. In such situations, the intrinsic features of MSCs become altered, thus
eventually impairing their therapeutic impact. Nevertheless, this concept is opposed by
Ivana Ferrero et al. who reported that MSCs obtained from patients with amyotrophic
lateral sclerosis (ALS) did not depict any notable functional or chromosomal alterations
compared to those obtained from healthy donors [137].
MSCs are famous of their tumor-oriented migration and/or incorporation explaining
their use as potential targeted carriers for antitumor drugs/genes. They are attracted to
the tumor site by tumor-secreted soluble factors. In addition to their anti-cancer features,
MSCs also show both pro-cancer aspects, thus found to be involved in various stages of
tumor progression [138]. Upon arrival to tumor, MSCs stimulate epithelial to mesenchymal
transition (EMT) of cancer cells. MSCs could also manipulate tumor microenvironment
(e.g., by angiogenesis, immunomodulation, etc.,), enhancing tumor progression [138].
Even more, MSCs might enhance the metastatic potential of cancerous cells [139]. On
the other side of tumor-MSCs bi-directional interactions, a variety of pro-tumor factors
secreted by tumor cells could affect the phenotypic features of MSCs, in addition to their
gene expression.
Another major concern with the use of MSCs in cell therapy is their ability to fuse
with host cells forming heterokaryons or entosis-derived hybrids with regenerative poten-
tial [140]. However, it is still critical to fully investigate the pros and cons of these hybrids.
Future studies are still needed to attest how synkaryons would divide and segregate their
chromosomes, producing stable/unstable hybrids with regenerative or oncogenic potential,
respectively [141]. In case MSCs were genetically modified, the consequences of cell fusion
might be even worse, leading to alteration of host cell genome. An attractive approach to
guard against damaging consequences of cell fusion is cell entrapment (e.g., microencap-
sulation, 3D-scaffolds, etc.,). Microencapsulation of human cells has been used for many
applications [142–144]. In particular, it is extremely useful during cell therapy, wherein
the membrane can create a barrier between the host cells and transplanted cells. MSCs
could be entrapped within various biomaterials (e.g., hyaluronic acid, alginate, agarose,
etc.,) that can also provide a physiologic environment that promotes cell survival [145],
functionality [110], and prevent immune response [146] and cell fusion. Even though
MSCs are immobilized within the microcapsules, they retain their paracrine functions,
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and manipulate their microenvironment, at the site of implantation, owing to the expres-
sion/overexpression of various therapeutic molecules. Moreover, the microencapsulation
per se is considered effective to evade any cell pro-oncogenic risk mediated by direct
contact with cancer cells [147].
6. Concluding Remarks
Genetically modified MSCs is an attractive tool that could be widely implemented
in clinical translation of promising therapeutics. Genetic manipulations in MSCs can be
mediated by various delivery systems to efficiently induce the expression, up-regulation,
or down-regulation of specific genes or pathways. However, such tool requires detailed
investigations on the safety and potency in short- and long-term. In this review we tried
to highlight the three main stakeholders of this process, namely the MSCs, nucleic acids,
and gene carriers, mainly the non-viral lipid vectors. We tried to emphasize the up-to-date
applications for each, as well as the challenges they face. Aiming for optimization of
MSCs as a gene delivery carrier, several aspects warrant improvement. The starting point
would be by focusing on the biology of MSCs, basically by obtaining cells from a proper
source, rightfully characterizing, and carefully expanding them; then, various gene delivery
complexes to be optimized for nontoxic transfection greater transgene expression. This
entails adequate selection of nucleic acids to match potential applications paying enough
attention to their cons and pros. Then, the nucleic acid carriers are optimized by deciding on
the suitable biodegradable components and the appropriate preparation method. Moreover,
we have highlighted some recent approaches (e.g., bioprinting, bioscaffolds, etc.,) designed
to enhance the therapeutic potential of MSCs by augmenting the engrafting niche and/or
boosting the targeted delivery for more potent and versatile therapies.
Funding: Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10)
of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and
technical assistance. The Department of Education, University and Research of the Basque Country
Government (Consolidated Groups, IT907-16); the Spanish Ministry of Science and Innovation
(GrantsPID2019-106199RB-C21).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation
Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the
intellectual and technical assistance. The Department of Education, University and Research of the
Basque Country Government; the Spanish Ministry of Science and Innovation.
Conflicts of Interest: The authors report no conflicts of interest in this work.
References
1. Attia, N.; Mashal, M. Mesenchymal Stem Cells: The Past Present and Future; Spinger: New York, NY, USA, 2020.
2. Mehanna, R.A.; Nabil, I.; Attia, N.; Bary, A.A.; Razek, K.A.; Ahmed, T.A.; Elsayed, F. The effect of bone marrow-derived
mesenchymal stem cells and their conditioned media topically delivered in fibrin glue on chronic wound healing in rats. BioMed
Res. Int. 2015, 2015. [CrossRef]
3. Afanasyev, B.V.; Elstner, E.E.; Zander, A.R. AJ Friedenstein, founder of the mesenchymal stem cell concept. Cell Ther. Transpl.
2009, 1, 35–38.
4. Friedenstein, A.J.; Petrakova, K.V.; Kurolesova, A.I.; Frolova, G.P. Heterotopic transplants of bone marrow. Transplant 1968, 6,
230–247. [CrossRef]
5. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8, 726–736. [CrossRef]
[PubMed]
6. Attia, N.; Khalifa, Y.H.; Rostom, D.M.; Mashal, M. Mesenchymal stem cells versus their extracellular vesicles in treatment of liver
fibrosis: Is it possible to compare? Med. Res. Arch. 2021, 9, 9. [CrossRef]
7. James, R.; Namitha, H.; Kaushik, D.D. Clinical applications of mesenchymal stem cells. In Biointegration of Medical Implant
Materials (Second Edition); Sharma, C.P., Ed.; Elsevier: Amsterdam, Netherlands, 2020; pp. 101–116.
Pharmaceutics 2021, 13, 843 23 of 28
8. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.C.; Krause, D.S.; Deans, R.J.; Keating, A.; Prockop, D.J.;
Horwitz, E.M. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular
Therapy position statement. Cytotherapy 2006, 8, 315–317. [CrossRef] [PubMed]
9. Yang, Y.-H.K.; Ogando, C.R.; See, C.W.; Chang, T.-Y.; Barabino, G.A. Changes in phenotype and differentiation potential of human
mesenchymal stem cells aging in vitro. Stem Cell Res. Ther. 2018, 9, 1–14. [CrossRef] [PubMed]
10. Yu, K.-R.; Lee, J.Y.; Kim, H.-S.; Hong, I.-S.; Choi, S.W.; Seo, Y.; Kang, I.; Kim, J.-J.; Lee, B.-C.; Lee, S.; et al. A p38 MAPK-Mediated
Alteration of COX-2/PGE2 Regulates Immunomodulatory Properties in Human Mesenchymal Stem Cell Aging. PLoS ONE 2014,
9, e102426. [CrossRef]
11. Sotirov, R.; Kostadinova, M.; Pashova, S.; Kestendjieva, S.; Vinketova, K.; Abadjieva, D.; Stoyanova, E.; Oreshkova, T.; Kistanova,
E.; Mourdjeva, M. Morphology of Mesenchymal Stem Cells in 3D spheroids. Acta Morphol. Anthropol. 2018, 25, 90–96.
12. Caplan, A.I. There Is No “Stem Cell Mess”. Tissue Eng. Part. B Rev. 2019, 25, 291–293. [CrossRef] [PubMed]
13. Dalkara, D.; Goureau, O.; Marazova, K.; Sahel, J.-A. Let There Be Light: Gene and Cell Therapy for Blindness. Hum. Gene Ther.
2016, 27, 134–147. [CrossRef] [PubMed]
14. Byrne, B.J. Neuromuscular Gene Therapy: Catching the Wave of Positive Early Studies Is Expected to Crest in Product Approvals.
Mol. Ther. 2019, 27, 1695–1696. [CrossRef] [PubMed]
15. Perrin, G.Q.; Herzog, R.W.; Markusic, D.M. Update on clinical gene therapy for hemophilia. Blood 2019, 133, 407–414. [CrossRef]
[PubMed]
16. Roma-Rodrigues, C.; Rivas-García, L.; Baptista, P.V.; Fernandes, A.R. Gene Therapy in Cancer Treatment: Why Go Nano?
Pharmaceutics 2020, 12, 233. [CrossRef]
17. Satija, N.; Singh, V.K.; Verma, Y.K.; Gupta, P.; Sharma, S.; Afrin, F.; Sharma, M.; Sharma, P.; Tripathi, R.P.; Gurudutta, G.U.
Mesenchymal stem cell-based therapy: A new paradigm in regenerative medicine. J. Cell. Mol. Med. 2009, 13, 4385–4402.
[CrossRef]
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